Congratulations to Louise Bouman, Member of the Board of the Alliance for Pulmonary Hypertension, for her election as Chair of the United Patient Advisory Group of the European Lung Foundation (ELF)!

At the Alliance for Pulmonary Hypertension we are very proud that Louise Bouman, Member of our Board, has been elected as Chair of the UPAG (United Patient Advisory Group) of the European Lung Foundation, United Patient Advisory Group within the European Lung Foundation (ELF), a collaborative network consisting of representatives from various condition-specific Patient Advisory […]

Congratulations to Louise Bouman, Member of the Board of the Alliance for Pulmonary Hypertension, for her election as Chair of the United Patient Advisory Group of the European Lung Foundation (ELF)! Read Post »

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026

French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program. Prostacyclins reduced pulmonary vascular resistance while significantly increasing cardiac index and right ventricular power — the heart working harder to push more blood through. Sotatercept

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026 Read Post »

AI imaging company Qureight brings together leading pulmonary hypertension experts on new Scientific Advisory Board, Biospace, May 5, 2026

Qureight is an end-to-end imaging Clinical Research Organization (CRO) that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease. It is developing its deep learning AI imaging models to support ongoing clinical trials in the pulmonary hypertension field, where there is demand for robust non-invasive ways to

AI imaging company Qureight brings together leading pulmonary hypertension experts on new Scientific Advisory Board, Biospace, May 5, 2026 Read Post »

New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension

New study aims to see how 24 weeks of triple therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept, affects pulmonary vascular resistance (PVR) in patients with newly diagnosed pulmonary arterial hypertension. SIRIUS is a 24-week, single-arm, open-label study with up to 42 days of screening and a 28-day safety follow-up.

New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension Read Post »

Cereno Scientific announces partnership with PHA Europe on patient-centered pulmonary hypertension drug design, May 11, 2026

Swedish biotech Cereno Scientific has announced a collaboration with PHA Europe & Global, aimed at integrating the patient perspective more systematically into clinical trial design and execution. Cereno is developing two experimental medications that could expand choices in this space: CS1 for pulmonary arterial hypertension (PAH) and CS014 for pulmonary hypertension associated with lung disease (PH-ILD). The

Cereno Scientific announces partnership with PHA Europe on patient-centered pulmonary hypertension drug design, May 11, 2026 Read Post »

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026

Researchers from China have traced the remarkable 30-year evolution of pulmonary arterial hypertension treatment, from a disease with no effective options to one on the cusp of a potential cure. What was once described as the “cancer of cardiovascular diseases” — with a median survival of just 2.8 years after diagnosis — has become a

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026 Read Post »

Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026

New pooled data presented in the form of a scientific poster at the American Thoracic Society 2026 International Conference in Orlando suggests that sotatercept may significantly reduce morbidity and mortality risks in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a particularly challenging population to treat. The analysis combined data from three phase

Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026 Read Post »

“Transplantation Roadmap: Understanding the Role of Risk Assessment in Your Pulmonary Hypertension Plan”, June 2, 2026, 3 p.m. EDT

The Pulmonary Hypertension Association, PHA, is hosting a free webinar on transplant evaluation for people living with pulmonary hypertension and their caregivers. The session will cover how risk assessment works, how risk scores guide transplant referral and timing, and what questions to ask your care team — with perspectives on both adult and paediatric patients.

“Transplantation Roadmap: Understanding the Role of Risk Assessment in Your Pulmonary Hypertension Plan”, June 2, 2026, 3 p.m. EDT Read Post »

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026

A 10-week fully remote, home-based exercise programme for people with pulmonary hypertension (pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) was found to be both acceptable and beneficial, according to a study conducted by a group of Irish researchers, based on qualitative interviews with 13 participants. The programme combined aerobic, resistance and respiratory

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026 Read Post »

Lung Transplant Recipient Reaches Record High Altitude on Mount Aconcagua (6,961 m) during a scientific expedition, Transplant International, May 12, 2026

A 51-year-old lung transplant recipient — transplanted in 2002 for cystic fibrosis — successfully reached the summit of Mount Aconcagua in Argentina (6,961 m) in January 2026, without supplemental oxygen. This is the highest altitude ever recorded for a lung transplant recipient. The achievement was part of an international medical expedition organised by the Vienna

Lung Transplant Recipient Reaches Record High Altitude on Mount Aconcagua (6,961 m) during a scientific expedition, Transplant International, May 12, 2026 Read Post »

When breath becomes music: a campaign to pay tribute to persons living with pulmonary arterial hypertension, World Pulmonary Hypertension Day, May 5, 2026

On 5 May, World Pulmonary Arterial Hypertension Day, a beautiful and unusual initiative brought the stories of people living with this rare condition to life in an unexpected way — through music. “Aria di vita” (“Breath of Life”) is a campaign promoted by MSD Italia, with the patronage of the two Italian pulmonary hypertension patient

When breath becomes music: a campaign to pay tribute to persons living with pulmonary arterial hypertension, World Pulmonary Hypertension Day, May 5, 2026 Read Post »

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial

This article is not new (it dates back to 2010) but we are publishing it because pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are often confused, whereas they are very different conditions with different diagnostic approaches and treatments. Mixing them up can lead to serious diagnostic and therapeutic errors. Key points: *Pulmonary hypertension is

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial Read Post »

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026

Researchers from Canada have published a review which summarizes recently established and emerging signalling pathways that may influence the next generation of targeted pulmonary arterial hypertension therapies. They note that the therapeutic landscape for this condition is moving towards mechanism-based approaches with the potential to alter the course of the disease. In particular, the transforming

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026 Read Post »

United Therapeutics presents positive data from ongoing research at the American Thoracic Society’s International Conference, May 15-20, Orlando (US)

United Therapeutics announced positive data from the TETON-1 phase 3 pivotal study of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF), and of the ADVANCE OUTCOMES and ARTISAN studies on pulmonary arterial hypertension at the American Thoracic Society’s International Conference on May 15-20, in Orlando (see also our previous article at this link) The following posters

United Therapeutics presents positive data from ongoing research at the American Thoracic Society’s International Conference, May 15-20, Orlando (US) Read Post »

CalciMedica advances novel oral therapy for pulmonary hypertension, PRN Newswire, May 12, 2026

CalciMedica, a clinical-stage biopharmaceutical company, is developing CM5480, an oral CRAC channel inhibitor, as a potential first-in-class therapy for pulmonary hypertension, including pulmonary arterial hypertension. The drug targets pulmonary vascular and right ventricular remodeling, which are key drivers of disease progression in pulmonary hypertension. Preclinical studies are currently underway to evaluate its pharmacology, safety and

CalciMedica advances novel oral therapy for pulmonary hypertension, PRN Newswire, May 12, 2026 Read Post »

Sotarcept has been approved in England and Wales by the National Institute for Health and Care Excellence (NICE), May 14, 2026

Sotatercept has been approved for use in eligible patients in England and Wales. The decision by the National Institute for Health and Care Excellence (NICE), announced on 14th May, means the drug (brand name Winrevair®) can be prescribed alongside existing pulmonary arterial hypertension treatments for patients who meet specific clinical criteria. The drug was approved

Sotarcept has been approved in England and Wales by the National Institute for Health and Care Excellence (NICE), May 14, 2026 Read Post »

Tenax Therapeutics reports progress on an investigational drug for World Health Organisation Group 2 pulmonary hypertension, BioSpace, May 12, 2026

Tenax Therapeutics has reported good progress on their Phase 3 LEVEL study investigating TNX-103, a therapy for PH-HFpEF – pulmonary hypertension associated with heart failure with preserved ejection fraction, Group 2 of the World Health Organisation, WHO, classification. Topline data expected in the third quarter of 2026, and enrolment is also advancing in LEVEL-2, a

Tenax Therapeutics reports progress on an investigational drug for World Health Organisation Group 2 pulmonary hypertension, BioSpace, May 12, 2026 Read Post »

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026

Assessment of exercise provides important prognostic information about pulmonary arterial hypertension patients. Researchers from the UK have recently published a review of current digital alternatives to traditional outcome measures. The 6-minute walk test (6MWT) is a key tool for monitoring pulmonary arterial hypertension, but since care is often centralized, patients may only do it once

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026 Read Post »

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026

Despite the comprehensive, evidence-based guidance offered by current international guidelines on the management of pulmonary hypertension, clinicians frequently encounter situations where the correct diagnosis or the most appropriate treatment remains uncertain. Methods A panel of pulmonary hypertension experts identified ten real-world diagnostic and management dilemmas during 2024–2025. For each, the available evidence was reviewed and

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026 Read Post »

South Korean biotech GI Innovation files patent for next-generation pulmonary arterial hypertension candidate, The Bio, April 29, 2026

GI Innovation, a South Korean bio-venture company, announced on April 29, 2026, that it has filed a domestic patent application for GI-214 (development code), a pulmonary arterial hypertension (PAH) treatment candidate. GI-214 is positioned as a next-generation candidate targeting the same disease-associated signaling pathway (the activin pathway) as sotatercept, the therapy developed by MSD (Merck

South Korean biotech GI Innovation files patent for next-generation pulmonary arterial hypertension candidate, The Bio, April 29, 2026 Read Post »

TRANSLATE »
Scroll to Top